Transplantation of cultured dental pulp stem cells into the skeletal muscles ameliorated diabetic polyneuropathy: therapeutic plausibility of freshly isolated and cryopreserved dental pulp stem cells
Stem Cell Research & Therapy volume 6, Article number: 162 (2015)
Dental pulp stem cells (DPSCs) are mesenchymal stem cells located in dental pulp and are thought to be a potential source for cell therapy since DPSCs can be easily obtained from teeth extracted for orthodontic reasons. Obtained DPSCs can be cryopreserved until necessary and thawed and expanded when needed. The aim of this study is to evaluate the therapeutic potential of DPSC transplantation for diabetic polyneuropathy.
DPSCs isolated from the dental pulp of extracted incisors of Sprague–Dawley rats were partly frozen in a −80 °C freezer for 6 months. Cultured DPSCs were transplanted into the unilateral hindlimb skeletal muscles 8 weeks after streptozotocine injection and the effects of DPSC transplantation were evaluated 4 weeks after the transplantation.
Transplantation of DPSCs significantly improved the impaired sciatic nerve blood flow, sciatic motor/sensory nerve conduction velocity, capillary number to muscle fiber ratio and intra-epidermal nerve fiber density in the transplanted side of diabetic rats. Cryopreservation of DPSCs did not impair their proliferative or differential ability. The transplantation of cryopreserved DPSCs ameliorated sciatic nerve blood flow and sciatic nerve conduction velocity as well as freshly isolated DPSCs.
We demonstrated the effectiveness of DPSC transplantation for diabetic polyneuropathy even when using cryopreserved DPSCs, suggesting that the transplantation of DPSCs could be a promising tool for the treatment of diabetic neuropathy.
Dental pulp stem cells (DPSCs), which are mesenchymal stem cells located in the dental pulp cavity [1, 2], are considered a possible cell source for regenerative medicine since DPSCs can be obtained from extracted teeth without an additional invasion, such as from wisdom teeth or premolars extracted for orthodontic reasons. DPSCs are highly proliferative and can differentiate into osteoblasts, odontoblasts, adipocytes, and neuronal cells [3, 4]. The clinical application of DPSCs is ongoing, such as for bone regeneration [5–7] and spinal cord injury .
Diabetic polyneuropathy (DPN) is the most common and early developing complication in both type 1 and type 2 diabetes . Its various symptoms not only reduce the quality of life, but the existence of DPN affects mortality . Although recent anti-symptomatic drugs are effective for diabetic nerve pain , a more effective treatment is needed to cure DPN.
We suggest that progenitor/stem cell transplantation is a potentially useful therapy for the treatment of DPN since it improves the nerve blood flow and nerve conduction velocity as well as the sensory disorder in diabetic animals [12–14]. However, previous investigations determined that the impairment of cell function by diabetes occurs in progenitor/stem cells [15–17]. Aging also impairs progenitor/stem cells [18, 19]. Recently, we demonstrated that the therapeutic efficacy of bone marrow-derived mononuclear cells (MNCs) for DPN was impaired in MNCs from aged rats compared with those from young rats .
DPSCs could be isolated from the teeth extracted by for orthodontic reasons in people by their 20s. If DPSCs isolated from young teeth can be cryopreserved for future use, some of the problems of diabetes and aging may be treated. In this paper, we investigated whether transplantation of DPSCs can improve DPN. Furthermore, to investigate the viability of cryopreserved DPSCs (cryo-DPSCs), we compared the proliferative and differential ability of freshly isolated DPSCs (fresh-DPSCs) and cryo-DPSCs and examined their therapeutic potential in DPN. We demonstrated that the transplantation of fresh-DPSCs into hindlimb skeletal muscles ameliorated the sciatic nerve blood flow and sciatic nerve conduction velocity in association with the increased capillary to muscle ratio and intra-epidermal nerve fiber density in diabetic rats. The cryo-DPSCs showed equivalent ability for proliferation and differentiation compared with the fresh-DPSCs. Cryo-DPSC transplantation showed equivalent efficacy for improving the nerve conduction velocity and nerve blood flow in diabetic rats.
Isolation of rat DPSCs
Dental pulp was harvested from the extracted incisors of 6-week-old male Sprague–Dawley rats (Chubu Kagakushizai, Nagoya, Japan) or green fluorescent protein (GFP)-transgenic SD rats (SD-Tg(CAG-EGFP)Cz-0040sb; Japan SLC, Inc., Hamamatsu, Japan). DPSCs were isolated from the dental pulp by digestion with phosphate-buffered saline containing 0.1 % collagenase and 0.25 % trypsin. DPSCs were cultured with alpha modification of the Eagle’s medium (α-MEM; GIBCO, Billings, MT, USA) supplemented with 20 % fetal bovine serum embryonic stem cell-qualified (GIBCO) . DPSCs from passage 3 to 6 were used for all experiments. All experimental protocols were conducted according to the Regulations for Animal Experiments in Aichi Gakuin University, and were approved by the Institutional Animal Care and Use Committees of Aichi Gakuin University.
Detection of cell surface markers
DPSCs at passage 3 were subjected to flow cytometric analysis (FACS Calibur; Becton Dickinson, Franklin Lakes, NJ, USA). Cells were stained with the FITC-conjugated mouse monoclonal antibody against rat CD90, the FITC-conjugated hamster antibody against rat CD29, and PE-conjugated mouse monoclonal antibodies against rat CD34, CD49d, and CD45 (Becton Dickinson). Isotype-identical antibodies served as controls. Data were analyzed with CELLQUEST software (Becton Dickinson) .
Animals and induction of diabetes
Six-week-old male Sprague–Dawley rats were provided by Chubu Kagakushizai. Diabetes was induced by the intraperitoneal injection of streptozotocine (STZ; 60 mg/kg; Sigma Chemical, St. Louis, MO, USA). Control rats received an equal volume of citric acid buffer.
Transplantation of DPSCs
Eight weeks after the induction of diabetes, 1 × 106 cells/limb of DPSCs in 1.0 ml saline were injected into 10 points in the unilateral hindlimb skeletal muscles of the normal and diabetic rats. Vehicle (saline) was injected into the hindlimb muscles of the other side as the control. Four weeks after the transplantation, the following measurements were performed.
Sciatic nerve conduction velocities
Rats were anesthetized with isopentane and placed on a heated pad in a room maintained at 25 °C to ensure a constant rectal temperature of 37 °C. Motor nerve conduction velocity (MNCV) between the ankle and sciatic notch, and sensory nerve conduction velocity (SNCV) in the sciatic nerve between the ankle and knee were measured using a Neuropak NEM-9400 instrument (Nihon-Koden, Osaka, Japan).
Sciatic nerve blood flow
Sciatic nerve blood flow (SNBF) was measured by laser-Doppler flowmeter (FLO-N1, Omegawave, Tokyo, Japan). The skin of an anesthetized rat was cut along the femur and then an incision through the fascia was carefully made to expose the sciatic nerve. The blood flow was measured by a laser-Doppler probe placed 1 mm above the nerve.
Rats were killed by an overdose of pentobarbital. The soleus muscles and footpads from both sides were obtained from the normal and the diabetic rats. Extracted tissues were fixed by 4 % paraformaldehyde overnight, and then embedded in paraffin.
Capillary number to muscle fiber ratio
The soleus muscles in paraffin were cut into 5-μm sections for immunohistochemical staining. The sections were incubated overnight at 4 °C with the primary antibody (anti-vWF polyclonal antibody; DAKO Japan, Tokyo, Japan) diluted 1:600 and subsequently stained using the Simplestain rat system (Nichirei, Tokyo, Japan) according to the manufacturer’s instructions. The negative control was performed by omitting the anti-vWF antibody.
The sections were also stained with the primary antibody (anti-PECAM-1 polyclonal antibody; Santa Cruz Biotechnology Inc., Dallas, TX, USA) diluted 1:200 and visualized using Alexa fluor 594 anti-rabbit secondary antibody (Invitrogen, Carlsbad, CA, USA). Nuclei were stained with 4’-6-diamidino-2-phenylindole (DAPI). The capillary to muscle ratio was counted under a fluorescence microscope (×200).
Location and differentiation of transplanted DPSCs in skeletal muscles
To investigate the survival and the differentiation of transplanted DPSCs, DPSCs isolated from GFP rats were transplanted into the hindlimb skeletal muscles of diabetic rats. Four weeks after the transplantation, the DPSC-transplanted skeletal muscles were excised and fixed in 4 % paraformaldehyde. The specimens were embedded within an OCT compound (Sakura Finetechnical, Tokyo, Japan) and cut into 5-μm sections. The sections were stained with the primary antibody against PECAM-1 (1:400), FABP (1:100), osteocalcin (1:100) (R&D Systems, Minneapolis, MN, USA), neuronal nuclei (NeuN) (1:400; Millipore, Billerica, MA, USA), and glial fibrillary acidic protein (1:400; Santa Cruz). After washing, the sections were incubated with the Alexa fluor 594-conjugated secondary antibodies. DAPI was detected as cell nuclei. Sections were observed under a fluorescence microscope FV10i confocal system (Olympus, Tokyo, Japan).
Intra-epidermal nerve fiber density
The paraffin-embedded footpads were cut into 8-μm sections. The sections were incubated overnight at 4 °C with the primary antibody (anti-PGP9.5 antibody; Abnova, Taipei City, Taiwan) diluted 1:400 and subsequently stained using the Simplestain rat system (Nichirei) according to the manufacturer’s instructions. The negative control was performed by omitting the anti-PGP9.5 antibody. Each individual nerve fiber with branching in the epidermis from the dermis was counted. Intra-epidermal nerve fiber density (IENFD) was measured blindly in 10 fields from each section by three independent investigators under light microscopy (×200) and was expressed as epidermal nerve fiber number per length of epidermal basement membrane [23, 24].
mRNA expression of cultured DPSCs and hindlimb skeletal muscles
RNA was extracted from cultured DPSCs and the frozen samples of hindlimb skeletal muscles using TRIzol Reagent (Invitrogen) according to the manufacturer’s instructions. Starting from 1 μg RNA, cDNA was synthesized using ReverTra Ace (Toyobo, Osaka, Japan) according to the manufacturer’s descriptions. Primers and probes for basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), nerve growth factor (NGF), neurotrophin-3 (NT-3) and 18S rRNA and β2 microglobulin for the endogenous control were purchased from Taqman Gene Expression Assays (Applied Biosystems, Foster City, CA, USA). Polymerase chain reaction (PCR) products were visualized by agarose gel (Wako, Osaka, Japan)/ethidium bromide (Sigma). Real-time quantitative PCR (qRT-PCR) was performed and monitored by the ABI PRISM 7000 Sequence Detction System (Applied Biosystems). The relative quantity was calculated by the by the ΔΔCt method.
Cryopreservation and thawing of DPSCs
After DPSCs were cultured at passage 3, the cells were harvested with trypsin-EDTA, resuspended with CELLBANKER (Amsbio, Cambridge, MA, USA) and frozen in a cryotube in a −80 °C freezer for 6 months.
When thawing, cells were immediately thawed in a 37 °C water bath and then added to 10 ml of the cultured medium containing fetal bovine serum. After the cells were washed three times with phosphate-buffered saline, thawed DPSCs were cultured in a plastic dish with α-MEM supplemented with 20 % fetal bovine serum and used as cryo-DPSCs.
Adipogenic or osteogenic differentiation assay
For the differentiation assay, fresh-DPSCs and cryo-DPSCs at passage 3 to 4 were cultured for 2–3 weeks in the induction medium according to the manufacturer’s instructions (R&D Systems). Adipogenic differentiation medium contained 1 % h-insulin, 2 % L-glutamine, 10 % mesenchymal cell growth supplement, 0.5 % dexamethasone, 0.2 % indomethacin, and 0.1 % 3-isobutyl-methyl-xanthine. Adipogenic maintenance medium contained 1 % h-insulin, 2 % L-glutamine, and 10 % mesenchymal cell growth supplement. For the detection of adipogenic differentiation, we stained the lipid accumulation with oil red O (Polyscience, Warrington, PA, USA).
Osteogenic induction medium contained 0.5 % dexamethasone, 2 % L-glutamine, 0.5 % ascorbate, 1 % β-glycerophosphate and 10 % mesenchymal cell growth supplement. We detected osteogenic differentiation with alkaline phosphatase (ALP) activity using an ALP detection kit (Millipore).
Fresh-DPSCs and cryo-DPSCs were seeded onto six-well plates at 1 × 104 cells/well. The growth of DPSCs was determined by cell counts at days 3 and 5 after seeding. When counting, the cells were harvested with 0.05 % trypsin and were centrifuged at 1200 rpm for 5 min. The cell number was counted with a hemocytometer.
The proliferative potential of DPSCs was assessed by the MTT assay according to the manufacturer’s procedure (Cayman Chemical Company, Ann Arbor, MI, USA). After 3 and 5 days of culture, cells were seeded in 96-well culture plates (1 × 103 cells/well) and incubated for another 6 h. Then MTT Reagent was added and the cells were incubated for 3 h to reveal the formazan dark crystals. Crystal-dissolving solution was added to each well and the absorbance was determined at 570 nm with a microplate reader.
All results are expressed as mean ± SEM. Statistical analysis was performed by Student's t-test for comparisons between two groups and one-way analysis of variance followed by Bonferroni correction for multiple comparisons. The significant difference was indicated at the P < 0.05 level.
Body weights and blood glucose concentrations of rats
At 12 weeks after STZ injection, diabetic rats showed severe hyperglycemia (normal rats: 95.5 ± 6.4 mg/dl; diabetic rats: 401.3 ± 43.7 mg/dl; P < 0.01) and significant reductions in body weight (normal rats: 510.5 ± 19.0 g; diabetic rats: 313.0 ± 23.9 g; P < 0.01).
Characteristics of DPSCs
Phase-contrast microscopic images of cultured DPSCs are shown in Fig. 1a. DPSCs were identified by their typical spindle-shape morphology. The surface markers of DPSCs showed high expression of CD29 and CD90, which are common stem cell markers in mesenchymal stem cells and DPSCs (Fig. 1b). DPSCs also showed relatively high expressions of CD49d, but lacked the expression of CD34 and CD45 . The purity of DPSCs was achieved by passages and we found approximately 90 % purity after 3 passages. The differentiation ability of cultured DPSCs has already been confirmed in our previous paper .
Fresh-DPSC transplantation ameliorates impaired MNCV, SNCV and SNBF in the diabetic rats
Eight-weeks after the STZ injection, we transplanted fresh-DPSCs into the unilateral hindlimb skeletal muscles. Neurophysiological measurements were performed at 4 weeks after DPSC transplantation. MNCV and SNCV in the vehicle-injected side of the diabetic rats were significantly reduced compared with those of the normal rats (Fig. 2a, b). DPSC transplantation significantly ameliorated both MNCV and SNCV in the DPSC-injected side compared with those in the vehicle-injected side of the diabetic rats (P < 0.01).
SNBF was also significantly decreased in the vehicle-injected side (P < 0.05), which was significantly augmented by the DPSC transplantation in the diabetic rats (P < 0.05) (Fig. 2c). Transplantation of DPSCs in the normal rats did not affect MNCV, SNCV, or SNBF.
Fresh-DPSC transplantation increases capillary density of skeletal muscles in the diabetic rats
The vasculatures in the soleus muscles were visualized by vWF immunostaining (Fig. 3a) and PECAM-1 immunofluorescence staining (Fig. 3b). Quantitative analyses revealed that the PECAM-1 positive endothelial cell to muscle fiber ratio was significantly reduced in the vehicle-injected side of diabetic rats compared with the normal rats (P < 0.01) (Fig. 3c). Transplantation of DPSCs significantly increased the PECAM-1 positive cell to muscle ratio in diabetic rats.
To confirm whether the increased capillaries are of host cell origin or from the differentiation into vascular endothelial cells from transplanted DPSCs, we transplanted GFP-DPSCs into diabetic rats. As shown in Fig. 3d, some of the PECAM-positive vascular endothelial cells are expressing GFP, indicating that transplanted DPSCs differentiated into vascular endothelial cells. Other PECAM-positive endothelial cells were of host origin.
Transplanted DPSCs derived from GFP rats existed in the skeletal muscles without differentiation into adipocytes, osteoblasts, neuronal cells, or Schwann cells
Transplanted GFP-DPSCs existed around the muscle bundles in the skeletal muscles. Immunohistological staining revealed that transplanted GFP-DPSCs have not differentiated into adipocytes, osteoblasts, neurons or Schwann cells (Figure S1 in Additional file 1).
Transplantation of fresh-DPSCs increases IENFD in the diabetic rats
To detect the sensory small nerve fiber damage in DPN, we analyzed IENFD at the footpad, which is established as a research tool for unmyelinated C and thinly myelinated A delta fibers and considered as a surrogate marker for small fiber neuropathy . Intra-epidermal nerve fibers were visualized by PGP9.5 immunostaining (Fig. 4a). Quantitative analyses revealed that IENFD was significantly reduced by 50 % in the vehicle-injected side of diabetic rats compared with the normal rats (P < 0.01) (Fig. 4b), which was ameliorated by the transplantation of fresh-DPSCs (P < 0.05).
Cultured DPSCs express mRNA expression of angiogenic and neurotrophic factors
To confirm whether cultured DPSCs express angiogenic and neurotrophic factors, we evaluated mRNA expression of VEGF, bFGF, NGF and NT-3 by RT-PCR. The products were visualized by agarose gel electrophoresis. As shown in Fig. 5a, DPSCs expressed all of these angiogenic and neurotrophic factors.
Transplantation of fresh-DPSCs into skeletal muscles tends to affect mRNA expression of neurotrophic and angiogenic factors
To investigate whether DPSC transplantation affects mRNA expression in the transplanted skeletal muscles, we measured angiogenic and neurotrophic gene expressions in the skeletal muscles on the transplanted side and the vehicle-injected side. As shown in Fig. 5b, the mRNA expression of angiogenic and neurotrophic factors, especially bFGF and NGF, in the skeletal muscles tended to be increased on the transplanted side compared with those on the vehicle-injected side in both normal and diabetic rats, although they were not significant.
Characteristics of cryo-DPSCs are similar to those of fresh-DPSCs
Cryo-DPSCs were thawed at 37 °C, re-cultured and expanded. The cryo-DPSCs showed the typical spindle-shaped morphology, which was the same as that of the fresh-DPSCs (Fig. 6a). The surface marker analysis revealed that cryo-DPSCs were positive for CD29, CD90 and CD49d and negative for CD34, CD45, which was the same pattern shown by the fresh-DPSCs (Fig. 6b).
Differential and proliferative capability are preserved in cryo-DPSCs
We assessed the capacity of fresh-DPSCs and cryo-DPSCs to differentiate into adipocytes and osteoblasts. After adipogenic induction for 3 weeks, the cells were stained with oil red O for the detection of adipogenesis. Lipid cluster-positive cells were equally detected in both fresh-DPSCs and cryo-DPSCs (Fig. 7a). For the osteogenic induction, cells were cultured in the osteogenic induction medium for 2 weeks. ALP was identified at similar levels in fresh-DPSCs and cryo-DPSCs (Fig. 7a).
We examined the proliferative potential of fresh-DPSCs and cryo-DPSCs by cell count and MTT assay. The growth rate was not different between fresh-DPSCs and cryo-DPSCs by cell count (Fig. 7b). MTT assay showed that there was no significant difference in the proliferative potential between fresh-DPSCs and cryo-DPSCs on day 3 and day 5 (Fig. 7c).
Impaired nerve function in the diabetic rats is ameliorated by the transplantation of cryo-DPSCs
We evaluated the effects of fresh-DPSC transplantation and cryo-DPSC transplantation on the nerve functions in the diabetic rats. Eight weeks after STZ injection, fresh-DPSCs or cryo-DPSCs were transplanted into the unilateral hindlimb skeletal muscles in the diabetic rats and neurophysiological measurements were performed 4 weeks after transplantation. As shown in Fig. 8, the delayed MNCV and SNCV in the vehicle-injected side of the diabetic rats were significantly augmented by cryo-DPSC transplantation as well as fresh-DPSC transplantation (P < 0.05 and P < 0.01, respectively). The transplantation of fresh-DPSCs and cryo-DPSCs significantly increased SNBF compared with that in the vehicle injection side in diabetic rats (P < 0.05). The level of MNCV, SNCV, and SNBF on the transplanted side did not significantly differ between transplantations of fresh-DPSCs and cryo-DPSCs.
In this study, we revealed that the transplantation of cultured DPSCs into the hindlimb skeletal muscles ameliorated DPN in rats. We compared the fresh-DPSCs with the cryo-DPSCs and revealed that the cryo-DPSCs were not inferior in proliferative and differential ability compared with the fresh-DPSCs, and maintained their therapeutic potential for DPN.
DPN, an early onset and most frequent complication in diabetic patients, results from the impairment of nerve blood flow and from metabolic disorders . Although recent anti-symptomatic drugs improve the symptoms of DPN, the establishment of more essential and effective treatments is needed. In this manuscript, we revealed that the transplantation of DPSCs into hindlimb skeletal muscles ameliorated the impaired MNCV, SNCV and SNBF in diabetic rats. The capillary to muscle fiber ratio of the diabetic rats was significantly reduced compared with that of normal rats, but was ameliorated by the transplantation of DPSCs. The diabetic rats also showed decreased IENFD on the footpad, and the transplantation of DPSCs increased IENFD on the footpad of the transplanted side. These results suggest that the transplantation of DPSCs, as well as the other types of mesenchymal stem cells, could have therapeutic potential for DPN with the improvement of both large and small size nerve fibers and nerve blood flow [14, 25].
Previous experimental and clinical studies indicated that vasodilator therapy has some promising effects on DPN [26, 27]. Here, we showed that DPSCs expressed angiogenic genes, such as bFGF and VEGF, and the DPSC transplantation into the hindlimb skeletal muscles increased microvasculatures in the skeletal muscles, accompanied with an increase in the sciatic nerve blood flow at the transplanted side. We used GFP-expressing DPSCs and confirmed that a small number of the transplanted DPSCs differentiated into vascular endothelial cells and directly participated in vasculogenesis, while other microvasculatures were of host origin. Although DPSCs can differentiate into many type of cells, most of which are mesodermal in origin such as osteoblast, adipocytes, and neurons [1, 21, 28, 29], we have not found any differentiation into osteoblast, adipocytes, neuronal cells, or Schwann cells. These results are consistent with the previous results of the therapeutic transplantation of other progenitor or stem cells [12, 14].
An important issue to be solved for autologous cell transplantation in diabetic patients is the functional disorder of progenitor and mesenchymal stem cells. Like other mature cells, the functions of progenitor and mesenchymal stem cells were impaired by hyperglycemia and aging [16–19]. The efficacy of progenitor and stem cell transplantation was affected by the activity of donor cells [18, 20, 30]. DPSCs are isolated from dental pulp and easily expanded in a culture condition. Dental pulp can be obtained from otherwise useless teeth extracted for orthodontic reasons. Previous investigations demonstrated that DPSCs isolated even 5 days after tooth extraction have high proliferative activity [31, 32]. Importantly, DPSCs were reported to maintain their proliferative and differential ability and keep their immunosuppressive activity even after cryopreservation [33, 34].
Our therapeutic strategy for DPSC transplantation to treat DPN is as follows: DPSCs are isolated from extracted teeth in young adults for orthodontic reasons. Obtained DPSCs are cryopreserved before use. Cryo-DPSCs are thawed and expanded in a culture condition as needed. Re-cultured DPSCs are transplanted for the treatment of DPN. To ensure the possibility of this strategy, we have investigated whether the transplantation of cryo-DPSCs ameliorated DPN in STZ-induced diabetic rats. We determined that the cryo-DPSC transplantation improved nerve conduction velocity and nerve blood flow as well as fresh-DPSC transplantation. We also confirmed that cryo-DPSCs expressed the same surface antigen pattern as the fresh-DPSCs, and kept their potential to differentiate into osteoblasts and adipocytes, which is consistent with the results of a previous investigation . The proliferative activity measured by cell count and MTT assay was the same level in fresh-DPSCs and cryo-DPSCs. These results indicate that DPSCs maintain their function and therapeutic efficacy for the treatment of DPN after cryopreservation.
We have not evaluated for how long a single transplantation of DPSCs keeps the amelioration of DPN. We evaluated the effects of DPSC transplantation 4 weeks after transplantation in this study. The studies on the transplantation of other types of cells, such as mesenchymal stem cells and endothelial progenitor cells, demonstrated that the stem/progenitor cell transplantation ameliorated DPN 3 days to 12 weeks after transplantation, suggesting that the effects maintain for at least 12 weeks [13, 14, 36]. Further study is required on this issue.
We demonstrated for the first time that the transplantation of fresh-DPSCs ameliorated nerve conduction velocity and nerve blood flow with an increase in IENFD in diabetic rats. Cultured DPSCs expressed angiogenic and neurotrophic factor genes, suggesting their multi-function. Cryo-DPSCs maintained the proliferative and differentiative potential at the same level as fresh-DPSCs and the effects of cryo-DPSC transplantation were not inferior to fresh-DPSC transplantation. Since DPSCs can be isolated from teeth extracted from young adults, the obtained DPSCs, which can be cryopreserved until needed, are not only youthful but also may be stem cells before the onset of diabetes. These findings suggest that DPSCs may be a promising cell source for the treatment of DPN.
Basic fibroblast growth factor
Cryopreserved dental pulp stem cell
Dental pulp stem cell
Fluorescence activated cell sorting
Freshly isolated dental pulp stem cell
Green fluorescent protein
Intra-epidermal nerve fiber density
Motor nerve conduction velocity
Nerve growth factor
Polymerase chain reaction
Protein gene product 9.5
Real-time quantitative polymerase chain reaction
Sciatic nerve blood flow
Sensory nerve conduction velocity
Vascular endothelial growth factor
von Willebrand factor
Alpha modification of the Eagle’s medium
Gronthos S, Brahim J, Li W, Fisher LW, Cherman N, Boyde A, et al. Stem cell properties of human dental pulp stem cells. J Dent Res. 2002;81:531–5.
Gronthos S, Mankani M, Brahim J, Robey PG, Shi S. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci U S A. 2000;97:13625–30.
Zhang W, Walboomers XF, Van Kuppevelt TH, Daamen WF, Van Damme PA, Bian Z, et al. In vivo evaluation of human dental pulp stem cells differentiated towards multiple lineages. J Tissue Eng Regen Med. 2008;2:117–25.
d'Aquino R, Graziano A, Sampaolesi M, Laino G, Pirozzi G, De Rosa A, et al. Human postnatal dental pulp cells co-differentiate into osteoblasts and endotheliocytes: a pivotal synergy leading to adult bone tissue formation. Cell Death Differ. 2007;14:1162–71.
d'Aquino R, De Rosa A, Lanza V, Tirino V, Laino L, Graziano A, et al. Human mandible bone defect repair by the grafting of dental pulp stem/progenitor cells and collagen sponge biocomplexes. Eur Cell Mater. 2009;18:75–83.
Giuliani A, Manescu A, Langer M, Rustichelli F, Desiderio V, Paino F, et al. Three years after transplants in human mandibles, histological and in-line holotomography revealed that stem cells regenerated a compact rather than a spongy bone: biological and clinical implications. Stem Cells Transl Med. 2013;2:316–24.
Laino G, d'Aquino R, Graziano A, Lanza V, Carinci F, Naro F, et al. A new population of human adult dental pulp stem cells: a useful source of living autologous fibrous bone tissue (LAB). J Bone Miner Res. 2005;20:1394–402.
Sakai K, Yamamoto A, Matsubara K, Nakamura S, Naruse M, Yamagata M, et al. Human dental pulp-derived stem cells promote locomotor recovery after complete transection of the rat spinal cord by multiple neuro-regenerative mechanisms. J Clin Invest. 2012;122:80–90.
Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care. 2004;27:1458–86.
Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285–93.
Vinik AI, Casellini CM. Guidelines in the management of diabetic nerve pain: clinical utility of pregabalin. Diabetes Metab Syndr Obes. 2013;6:57–78.
Naruse K, Hamada Y, Nakashima E, Kato K, Mizubayashi R, Kamiya H, et al. Therapeutic neovascularization using cord blood-derived endothelial progenitor cells for diabetic neuropathy. Diabetes. 2005;54:1823–8.
Naruse K, Sato J, Funakubo M, Hata M, Nakamura N, Kobayashi Y, et al. Transplantation of bone marrow-derived mononuclear cells improves mechanical hyperalgesia, cold allodynia and nerve function in diabetic neuropathy. PLoS One. 2011;6:e27458.
Shibata T, Naruse K, Kamiya H, Kozakae M, Kondo M, Yasuda Y, et al. Transplantation of bone marrow-derived mesenchymal stem cells improves diabetic polyneuropathy in rats. Diabetes. 2008;57:3099–107.
Kim H, Han JW, Lee JY, Choi YJ, Sohn YD, Song M, et al. Diabetic mesenchymal stem cells are ineffective for improving limb ischemia due to their impaired angiogenic capability. Cell Transplant. 2014. doi:10.3727/096368914X682792.
Nakamura N, Naruse K, Kobayashi Y, Matsuki T, Hamada Y, Nakashima E, et al. High glucose impairs the proliferation and increases the apoptosis of endothelial progenitor cells by suppression of Akt. J Diabetes Invest. 2011;2:262–70.
Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation. 2002;106:2781–6.
Dimmeler S, Leri A. Aging and disease as modifiers of efficacy of cell therapy. Circ Res. 2008;102:1319–30.
Zhang Z, Zhao C, Liu B, Liang D, Qin X, Li X, et al. Inositol pyrophosphates mediate the effects of aging on bone marrow mesenchymal stem cells by inhibiting Akt signaling. Stem Cell Res Ther. 2014;5:33.
Kondo M, Kamiya H, Himeno T, Naruse K, Nakashima E, Watarai A, et al. Therapeutic efficacy of bone marrow‐derived mononuclear cells in diabetic polyneuropathy is impaired with aging or diabetes. J Diabetes Invest. 2014;6:140–9.
Hata M, Naruse K, Ozawa S, Kobayashi Y, Nakamura N, Kojima N, et al. Mechanical stretch increases the proliferation while inhibiting the osteogenic differentiation in dental pulp stem cells. Tissue Eng Part A. 2013;19:625–33.
Lindroos B, Maenpaa K, Ylikomi T, Oja H, Suuronen R, Miettinen S. Characterisation of human dental stem cells and buccal mucosa fibroblasts. Biochem Biophys Res Commun. 2008;368:329–35.
Quattrini C, Tavakoli M, Jeziorska M, Kallinikos P, Tesfaye S, Finnigan J, et al. Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes. 2007;56:2148–54.
Vinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. Diabetologia. 2000;43:957–73.
Yang Z, Li K, Yan X, Dong F, Zhao C. Amelioration of diabetic retinopathy by engrafted human adipose-derived mesenchymal stem cells in streptozotocin diabetic rats. Graefes Arch Clin Exp Ophthalmol. 2010;248:1415–22.
Malik RA, Williamson S, Abbott C, Carrington AL, Iqbal J, Schady W, et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet. 1998;352:1978–81.
Hotta N, Koh N, Sakakibara F, Nakamura J, Hamada Y, Hara T, et al. Effects of beraprost sodium and insulin on the electroretinogram, nerve conduction, and nerve blood flow in rats with streptozotocin-induced diabetes. Diabetes. 1996;45:361–6.
Arthur A, Rychkov G, Shi S, Koblar SA, Gronthos S. Adult human dental pulp stem cells differentiate toward functionally active neurons under appropriate environmental cues. Stem Cells. 2008;26:1787–95.
Alge DL, Zhou D, Adams LL, Wyss BK, Shadday MD, Woods EJ, et al. Donor-matched comparison of dental pulp stem cells and bone marrow-derived mesenchymal stem cells in a rat model. J Tissue Eng Regen Med. 2010;4:73–81.
Liang H, Hou H, Yi W, Yang G, Gu C, Lau WB, et al. Increased expression of pigment epithelium-derived factor in aged mesenchymal stem cells impairs their therapeutic efficacy for attenuating myocardial infarction injury. Eur Heart J. 2013;34:1681–90.
Suchanek J, Soukup T, Ivancakova R, Karbanova J, Hubkova V, Pytlik R, et al. Human dental pulp stem cells—isolation and long term cultivation. Acta Medica (Hradec Kralove). 2007;50:195–201.
Perry BC, Zhou D, Wu X, Yang FC, Byers MA, Chu TM, et al. Collection, cryopreservation, and characterization of human dental pulp-derived mesenchymal stem cells for banking and clinical use. Tissue Eng Part C Methods. 2008;14:149–56. doi:10.1089/ten.tec.2008.0031.
Papaccio G, Graziano A, d'Aquino R, Graziano MF, Pirozzi G, Menditti D, et al. Long-term cryopreservation of dental pulp stem cells (SBP-DPSCs) and their differentiated osteoblasts: a cell source for tissue repair. J Cell Physiol. 2006;208:319–25.
Pierdomenico L, Bonsi L, Calvitti M, Rondelli D, Arpinati M, Chirumbolo G, et al. Multipotent mesenchymal stem cells with immunosuppressive activity can be easily isolated from dental pulp. Transplantation. 2005;80:836–42.
Lee SY, Huang GW, Shiung JN, Huang YH, Jeng JH, Kuo TF, et al. Magnetic cryopreservation for dental pulp stem cells. Cells Tissues Organs. 2012;196:23–33.
Kim H, Park JS, Choi YJ, Kim MO, Huh YH, Kim SW, et al. Bone marrow mononuclear cells have neurovascular tropism and improve diabetic neuropathy. Stem Cells. 2009;27:1686–96.
We thank Mr. Brent Bell for reading the manuscript.
This research was supported in part by Grant-in-Aid for Scientific Research (21592506) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) and in part by the “Strategic Research AGU-Platform Formation (2008–2012)” Project for Private Universities from MEXT. The authors declare that they have no competing interests.
MH performed the experiments and wrote the manuscript with the help of MO, YK, NN, TT and MM. NK and SO contributed to isolate and characterize DPSCs. KK and HM contributed to histological procedures. YT and TM interpreted the data. KN conceived and designed the research. All authors read and approved the manuscript.
Transplanted GFP-expressing DPSCs were located in the skeletal muscles without differentiation into adipocytes, osteoblasts, neuronal cells, or Schwann cells. DPSCs from GFP-expressing rats were transplanted into hindlimb skeletal muscles in the diabetic rats. To analyze the differentiation of transplanted DPSCs, The skeletal muscles were stained with the primary antibody against FABP for adipocytes, osteocalcin for osteoblasts, neuronal nuclei (NeuN) for neurons and glial fibrillary acidic protein for Schwann cells. (PPTX 409 kb)
About this article
Cite this article
Hata, M., Omi, M., Kobayashi, Y. et al. Transplantation of cultured dental pulp stem cells into the skeletal muscles ameliorated diabetic polyneuropathy: therapeutic plausibility of freshly isolated and cryopreserved dental pulp stem cells. Stem Cell Res Ther 6, 162 (2015). https://doi.org/10.1186/s13287-015-0156-4